Results 41 to 50 of about 2,771 (190)

Modulation of tumor growth by crossreacting isoantibodies

open access: yesBiomedicine & Pharmacotherapy, 2002
Tumor cells transfected with strong antigenic epitopes were able to stimulate humoral response against relevant wild-type tumors. Crossreacting immune sera have been obtained by immunizing C57BL/6 mice with OVA-transfected leukemia EL-4 (subclone E.G7) and OVA-transfected melanoma B16 (subclone MO.5) stimulated with interferon-gamma.
P Nguyen, Van Binh   +2 more
openaire   +2 more sources

Fucosylation limits ADCC in clinically used anti‐RhD monoclonal antibodies

open access: yesTransfusion, EarlyView.
Abstract Background Haemolytic disease of the fetus and newborn (HDFN) is caused by maternal alloantibodies, often targeting the D antigen on fetal red blood cells. Maternal immunization is preventable with timely administration of anti‐D polyclonal antibodies (pAbs).
Gabriela Koike   +33 more
wiley   +1 more source

Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh‐mismatched transfusions in children?

open access: yesTransfusion, EarlyView.
Abstract Background RhD mismatched transfusions in RhD negative women have the potential to impact future pregnancies through alloimmunization and development of hemolytic disease of the fetus and newborn (HDFN). As use of RhD positive emergency‐release blood products in pediatric trauma has increased, it has become clear that a significant ...
Kirea Lange   +7 more
wiley   +1 more source

The incidence of ABO, Kell and Rh system blood groups in general population of Qazvin, Iran [PDF]

open access: yes, 2019
    Introduction:ABO antigens and the glycoproteins constituting the blood groups such as Kell and Rh systems are the mostly focused blood groups in transfusion medicine.
Ahmadi, Mohammad Hossein   +6 more
core   +2 more sources

Routine transfusion of Rh(D)‐positive RBCs to Rh(D)‐negative patients designated as do not resuscitate conserves Rh(D)‐negative red blood cell inventory

open access: yesTransfusion, EarlyView.
Abstract Background A minority of blood donors are Rh(D)‐negative, and Rh(D)‐negative red blood cell (RBC) products are often overutilized. As such, Rh(D)‐negative RBCs may be difficult to maintain in blood bank inventory. Study Design and Methods We changed our blood bank laboratory policy to approve non‐alloimmunized Rh(D)‐negative patients to ...
Julie Katz Karp   +5 more
wiley   +1 more source

The influence of season, photoperiod, and pineal melatonin on immune function. [PDF]

open access: yes, 1995
In addition to the well-documented seasonal cycles of mating and birth, there are also significant seasonal cycles of illness and death among many animal populations.
Demas, G   +3 more
core   +1 more source

Differential complement activation by alloantibodies in sickle cell hyperhaemolysis syndrome may influence disease course

open access: yes
British Journal of Haematology, EarlyView.
Mamie M. Thant   +4 more
wiley   +1 more source

Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine

open access: yesTransfusion, EarlyView.
Abstract Background Blood bank identification of antibodies against high‐prevalence antigens remains a challenge due to the scarcity of antigen‐negative reagent red cells sourced from blood donors. The MAM antigen, encoded by EMP3, is one such antigen associated with red cell alloimmunization and hemolytic disease of the fetus and newborn. Study Design
Naomi Gunawardena   +9 more
wiley   +1 more source

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

open access: yesTransfusion, EarlyView.
Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza   +11 more
wiley   +1 more source

International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences

open access: yesVox Sanguinis, EarlyView.
Abstract Background and Objectives Daratumumab, a therapeutic human anti‐CD38 monoclonal antibody, improves multiple myeloma outcomes but interferes with pre‐transfusion testing by binding CD38 on reagent red blood cells (RBCs), potentially masking clinically significant alloantibodies.
Arnaud Reggiani   +30 more
wiley   +1 more source

Home - About - Disclaimer - Privacy